Pacific Biosciences of California, Inc. (NASDAQ:PACB)

CAPS Rating: 3 out of 5

Results 1 - 20 of 27 : 1 2 Next »

Recs

0
Member Avatar jdubbau (88.10) Submitted: 9/4/2014 7:15:17 AM : Outperform Start Price: $5.16 PACB Score: -0.56

Long term trend of genomic sequencing in health care applications will create a new competitive landscape. Pacific Bio has a differentiated approach that will attract a segment of the (growing) market.

Recs

0
Member Avatar waynehe (83.12) Submitted: 3/3/2014 8:38:44 PM : Outperform Start Price: $6.87 PACB Score: -32.98

things are improving under new management

Recs

0
Member Avatar champagnepowder (78.20) Submitted: 2/26/2014 4:26:21 PM : Outperform Start Price: $7.19 PACB Score: -37.58

Technology is rule breaking and management is focused on improving throughput. Sales have been going up and industry seems to be providing some free promotion with all the papers that are being written/published.

Recs

0
Member Avatar rcwcfa (< 20) Submitted: 9/5/2013 11:23:48 AM : Underperform Start Price: $1.94 PACB Score: -112.82

The company is selling short term investments and stock in order to keep cash at a minimal level. Unless something actually sells, the company will either need to go to the well again or go insolvent.

Recs

0
Member Avatar elks20 (< 20) Submitted: 5/26/2013 7:26:38 AM : Outperform Start Price: $2.68 PACB Score: +71.49

New product, product updates, growth ahead

Recs

0
Member Avatar panesh (65.76) Submitted: 1/24/2013 11:47:01 AM : Outperform Start Price: $2.49 PACB Score: +72.41

This stock has been much higher than this and will return to 2 bagger status

Recs

0
Member Avatar gtechie (64.01) Submitted: 1/15/2013 2:58:49 PM : Outperform Start Price: $2.79 PACB Score: +47.42

Has it finally turned the corner? It's been up pretty big lately, and I'm making a CAPS bet that it'll continue.

Recs

0
Member Avatar mattyabe (51.41) Submitted: 6/23/2012 9:17:32 PM : Outperform Start Price: $2.00 PACB Score: +104.85

Both PACB and GNOM are beat up right now, and it's only a matter of time before one of them takes off. It may be smart to buy both instead of guessing which one

Recs

1
Member Avatar DebbyDo101 (20.27) Submitted: 3/25/2012 2:55:24 AM : Outperform Start Price: $3.99 PACB Score: -14.25

This is the risky one, but they will either pull the rabbit out of the hat or not. They have a machine that does gene resequencing for about a thousand dollars.
A stock at the price I would be willing to invest in because I believe in the product and will put some money behind it. Just not a lot of money. All I can lose is 3.93 a share.

Recs

0
Member Avatar CATomla (< 20) Submitted: 2/7/2012 12:57:52 PM : Outperform Start Price: $4.87 PACB Score: -43.80

No place to go but up.

Recs

0
Member Avatar badgervb (< 20) Submitted: 10/3/2011 11:45:08 PM : Underperform Start Price: $2.97 PACB Score: +12.64

investigation...and i own some. i am the kiss of death!

Recs

3
Member Avatar NeuroNerd (< 20) Submitted: 9/30/2011 1:24:34 PM : Outperform Start Price: $3.41 PACB Score: -24.75

The floor where I work just received one of their next-gen sequencers. It is quite possibly the coolest thing I have ever seen. I think it is fair to say that adoption will be slower than management's original optimistic projections because of the price tag; however, my suspicion is that the razor-and-blade model will allow them to eventually become profitable as specialized centers like ours adopt them. They really do have capabilities that leave the competition in the dust for certain applications.

Recs

0
Member Avatar Keekers44 (78.85) Submitted: 9/3/2011 12:39:41 PM : Outperform Start Price: $5.79 PACB Score: -87.28

This highly volitile stock is definately a speculative play for a while. Shares droped 30% after some bad news regarding gross margins. I believe that drop was a bit drastic.

Recs

0
Member Avatar Blackarrow1969 (34.39) Submitted: 8/5/2011 6:51:37 PM : Outperform Start Price: $6.45 PACB Score: -92.58

They had a great quarterly report but got creamed due to a JPM downgrade. It's a long-term spec stock with great potential.

Recs

0
Member Avatar johnnymack91362 (75.34) Submitted: 6/30/2011 1:47:50 PM : Outperform Start Price: $11.63 PACB Score: -108.67

gamble time

Recs

0
Member Avatar mtnv110960 (65.89) Submitted: 6/24/2011 7:39:58 PM : Outperform Start Price: $11.46 PACB Score: -110.35

Mark this date down. Who buys 1.5 million shares after hours? Something is going on.............

Recs

0
Member Avatar latinoeconomist (23.89) Submitted: 6/23/2011 4:34:32 AM : Outperform Start Price: $10.83 PACB Score: -110.97

Is gearing up for explosive growth.

Recs

0
Member Avatar polterziets (< 20) Submitted: 6/4/2011 5:03:54 PM : Outperform Start Price: $11.54 PACB Score: -110.33

i like where their technology is going

Recs

0
Member Avatar simsimmarvin38 (< 20) Submitted: 5/29/2011 3:42:29 AM : Outperform Start Price: $12.20 PACB Score: -107.36

Clearly the most powerful technology with a large void to fill in the sequencing space. Granted it will have a slow start as centers have to phase out current technology over time but once momentum picks up this run will be hard to stop.

Recs

0
Member Avatar TheChronos (98.30) Submitted: 5/24/2011 12:38:18 PM : Outperform Start Price: $11.73 PACB Score: -108.78

Beaten down after not living up to product performance promises made to initial investors:
http://www.fool.com/investing/high-growth/2011/05/13/pacific-biosciences-has-a-pr-problem.aspx?source=itxsitmot0000001&lidx=2

BUT, beaten down price does not consider the amount of revenue it is still capable of generating (plus over $30M of orders in the short term):

http://www.fool.com/investing/high-growth/2011/05/23/2-must-own-tech-stocks-and-1-to-watch.aspx?source=ihpsitth0000001

Results 1 - 20 of 27 : 1 2 Next »

Featured Broker Partners


Advertisement